Gerald Gauthier

Array ( [id] => 18863328 [patent_doc_number] => 20230417764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => METHODS FOR TREATING DRUG RESISTANT CANCERS [patent_app_type] => utility [patent_app_number] => 18/195184 [patent_app_country] => US [patent_app_date] => 2023-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18195184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003618 [patent_doc_number] => 20240067689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/312045 [patent_app_country] => US [patent_app_date] => 2023-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830850 [patent_doc_number] => 20230399375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 18/300919 [patent_app_country] => US [patent_app_date] => 2023-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526690 [patent_doc_number] => 20240350592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION [patent_app_type] => utility [patent_app_number] => 18/299480 [patent_app_country] => US [patent_app_date] => 2023-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096433 [patent_doc_number] => 20240115660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => SOLUBLE TREM2 PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/297805 [patent_app_country] => US [patent_app_date] => 2023-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20185937 [patent_doc_number] => 12397037 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Methods and compositions for immunomodulation [patent_app_type] => utility [patent_app_number] => 18/296510 [patent_app_country] => US [patent_app_date] => 2023-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 57 [patent_no_of_words] => 27107 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628482 [patent_doc_number] => 20230287347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => EXOSOME FOR STIMULATING T CELL AND PHARMACEUTICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/295631 [patent_app_country] => US [patent_app_date] => 2023-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18295631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806975 [patent_doc_number] => 20230381308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/191712 [patent_app_country] => US [patent_app_date] => 2023-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19947090 [patent_doc_number] => 12318428 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => VEGFR fusion protein pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 18/185443 [patent_app_country] => US [patent_app_date] => 2023-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 24 [patent_no_of_words] => 17720 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18185443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20158400 [patent_doc_number] => 12385012 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Methods and compositions for inducing hematopoietic cell differentiation [patent_app_type] => utility [patent_app_number] => 18/183804 [patent_app_country] => US [patent_app_date] => 2023-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 63 [patent_no_of_words] => 42766 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18183804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20756217 [patent_doc_number] => 12648966 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => Hematopoietic stem cell engraftment [patent_app_type] => utility [patent_app_number] => 18/121468 [patent_app_country] => US [patent_app_date] => 2023-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 20 [patent_no_of_words] => 9999 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18121468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19731263 [patent_doc_number] => 12209254 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => Human otic progenitor identification and isolation [patent_app_type] => utility [patent_app_number] => 18/182829 [patent_app_country] => US [patent_app_date] => 2023-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 10735 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18182829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844509 [patent_doc_number] => 20230406913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => METHOD FOR TREATING SARS-COV-2 INFECTIOUS DISEASE [patent_app_type] => utility [patent_app_number] => 18/181881 [patent_app_country] => US [patent_app_date] => 2023-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18181881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808654 [patent_doc_number] => 20230382988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/178783 [patent_app_country] => US [patent_app_date] => 2023-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18178783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770841 [patent_doc_number] => 20230365641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => TARGETED CYTOKINES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/115527 [patent_app_country] => US [patent_app_date] => 2023-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18115527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739597 [patent_doc_number] => 20230348555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => SOLUBLE CD33 FOR TREATING MYELODYSPLASTIC SYNDROMES (MDS) [patent_app_type] => utility [patent_app_number] => 18/171600 [patent_app_country] => US [patent_app_date] => 2023-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18171600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673149 [patent_doc_number] => 20230310636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 18/169497 [patent_app_country] => US [patent_app_date] => 2023-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18169497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986448 [patent_doc_number] => 20240058417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => AMELIORATION AND TREATMENT OF INFARCTION DAMAGE [patent_app_type] => utility [patent_app_number] => 18/167265 [patent_app_country] => US [patent_app_date] => 2023-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18167265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18726169 [patent_doc_number] => 20230340426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => PROTEIN-BASED PURIFICATION MATRICES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/158255 [patent_app_country] => US [patent_app_date] => 2023-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20264163 [patent_doc_number] => 12435139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Antibody constructs for DLL3 and CD3 [patent_app_type] => utility [patent_app_number] => 18/069704 [patent_app_country] => US [patent_app_date] => 2022-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 46895 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 355 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069704 [rel_patent_id] =>[rel_patent_doc_number] =>)